• Successful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicines
• Acquired portfolio complements existing Sandoz portfolio and consists primarily of off-patent branded medicines with focus on anaesthetics and specialty brands
• Transaction enables Sandoz to increase portfolio and pipeline offerings in hospital setting, expanding number of patients who can gain access to these important medicines  

Holzkirchen, …

• Sandoz officially recognized by Top Employers Institute for its exceptional employee offerings globally
• People-first policies such as global equal parental leave for 14 weeks and joining the Equal Pay International Coalition contributed to recognition
• Second such annual certification for Sandoz, underlining ongoing commitment to attract and keep best talent by building a great place to work

Holzkirchen, January 30, 2020 – Sandoz, a Novartis division, is pleased to announce that it has been officially awarded the “Global Top Employer 2020” …

• Full year net sales for continuing operations¹ up 9% (cc², +6% USD):
  • Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 million
  • Oncology BU growing 10% (cc) driven by Promacta/Revolade USD 1.4 billion (+23% cc), Kisqali USD 0.5 billion (+111% cc) and Lutathera USD 0.4 billion (+160% cc)
  • Sandoz sales grew 2% (cc, -1% USD) driven by Biopharmaceuticals …

• Full year net sales for continuing operations¹ up 9% (cc², +6% USD):
  • Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 million
  • Oncology BU growing 10% (cc) driven by Promacta/Revolade USD 1.4 billion (+23% cc), Kisqali USD 0.5 billion (+111% cc) and Lutathera USD 0.4 billion (+160% cc)
  • Sandoz sales grew 2% (cc, -1% USD) driven by Biopharmaceuticals …

• Mayzent^® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe¹
   
• Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not have an oral treatment that has been shown to be effective in delaying progression in this patient population
   
• Approval is based on the Phase III EXPAND trial, the largest randomized clinical study in a broad range of SPMS patients, …